Delivery Order SPE2DB20D1109-SPE2DB25FP81P
- Not listed
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $7,810.81 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The contract, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $19,051.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The award, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in treating inflammatory conditions. The contract was awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $10,098.59, represents a competitive award with no set-aside designation and is scheduled for completion by September 11, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $7,652.27 and is scheduled for completion by September 16, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, awarded on April 21, 2025, represents a competitively awarded contract with no set-aside designation and is scheduled for completion by April 22, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls, a pharmaceutical product for treating autoimmune conditions. The contract, awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. Performance will be executed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,926.76 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used for autoimmune disease treatment. The contract, awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, carries firm fixed pricing and was competitively awarded with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,394.58 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used to treat inflammatory conditions. The contract was awarded on August 19, 2025, with a completion date of August 20, 2025, and employs firm fixed price pricing with no set-aside designation. The product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP81PDelivery Order
The Defense Logistics Agency has awarded a delivery order valued at $4,531.80 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, issued on September 23, 2025, with an ultimate completion date of September 24, 2025, represents a non-competitive set-aside contract. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary pharmaceutical distribution operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen leverages this comprehensive global pharmaceutical support vehicle to supply an extensive range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs and other federal health systems worldwide. The company's contract portfolio demonstrates consistent capability in fulfilling federal medical procurement requirements across multiple therapeutic domains through competitively awarded delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 9/23/25 |